Table 4

Effects of PPAR ligands on AOM and/or DSS-induced ACF formation in male F344 rats (experiment 3)

Group no.Treatment (n)Body weight (g)Liver weight (g)Relative liver weight (g/100 g body weight)ACF/colonACs/focusAgNORs index
1AOM alone (8)234 ± 7a10.5 ± 1.44.5 ± 0.4984 ± 132.0 ± 0.211.6 ± 0.21b
21% DSS + AOM (10)226 ± 711.0 ± 1.54.9 ± 0.65115 ± 222.4 ± 0.291.9 ± 0.13
31% DSS + AOM + 0.01% pioglitazone (7)231 ± 1711.0 ± 0.64.8 ± 0.3471 ± 24c1.8 ± 0.17d1.2 ± 0.22e
41% DSS + AOM + 0.01% troglitazone (7)219 ± 89.7 ± 0.64.4 ± 0.3357 ± 14e1.6 ± 0.14e0.9 ± 0.15e
51% DSS + AOM + 0.01% bezafibrate (7)216 ± 914.2 ± 1.8c6.5 ± 0.63d59 ± 18f1.7 ± 0.16g0.9 ± 0.16e
60.01% pioglitazone (4)250 ± 79.7 ± 1.43.9 ± 0.57000.8 ± 0.12
70.01% troglitazone (4)222 ± 811.0 ± 1.04.9 ± 0.36000.7 ± 0.19
80.01% bezafibrate (4)225 ± 611.7 ± 0.65.2 ± 0.26000.7 ± 0.11
9None (4)221 ± 810.2 ± 1.04.5 ± 0.34000.7 ± 0.09
  • a Mean ± SD.

  • b Significantly different from group 9: P < 0.001.

  • c P < 0.05;

  • d P < 0.01;

  • e P < 0.001;

  • f P < 0.005;

  • g P < 0.002.